About us

Management Team

Kenneth Graabek Johansen

Acting CEO & CFO


Kenneth Graabek Johansen (b. 1976) is CFO of 2cureX AB and 2cureX A/S since 2021.

Read more
Kenneth Graabek Johansen
Acting CEO & CFO

Kenneth Graabek Johansen (b. 1976) is CFO of 2cureX AB and 2cureX A/S since 2021.

With more than 15 years of experience in business development and financial administration from the intersection of the biomedical area and advanced data analysis, Kenneth is fully engaged in delivering excellent business operations. More recent and relevant experience includes COO of JADBio (Greece), CEO of Raven biosciences (DK), CEO of QIAGEN Aarhus (DK) and CFO of CLC bio (DK).

In addition, he has several years working in audit with KPMG (DK), and holds a BA in Financial Management and Accounting.

2cureX share ownership and warrants
4 000 shares

Manuel Fernández

Quality & Regulatory Director


Manuel Fernández joined 2cureX in 2022 as Director of Quality & Regulatory.

Read more
Manuel Fernández
Quality & Regulatory Director

Manuel Fernández joined 2cureX in 2022 as Director of Quality & Regulatory.

Manuel has nearly 30 years’ experience in Diagnostics and Medical Devices. His academic background is in mechatronics, robotics and automation engineering, as well as biomedical engineering Bachelor’s Degree. He also completed Masters Degree in Clinical Engineering and Radiation Physics.

Throughout his career he has led the QA / RA function in several companies, becoming an expert in all relevant ISO norms. He has deep knowledge of the regulatory landscapes in Europe, US, China and Asia Pacific, and has been part of Notified Bodies, (BSI), as well working with competent regulatory authorities in major countries. He is a certified FDA-MDSAP Auditor, certified ISO 13485, ISO 27001 and ISO9001 Lead Auditor, certified FDA-Clinical Investigator Inspector and certified FDA Pharmaceutical QMS Auditor, among others.

2cureX share ownership and warrants
0 shares

Grith Hagel

Vice-President of Innovation


Grith Hagel (b. 1959) is VP of Innovation and Founder of 2cureX.

Read more
Grith Hagel
Vice-President of Innovation

Grith Hagel (b. 1959) is VP of Innovation and Founder of 2cureX.

Grith holds a degree of Biomedical Laboratory Science.

Grith has comprehensive experience in developing and running drug screening campaigns. Grith is the inventor of several patents on advanced cell-based, high throughput screening technologies. She is a co-founder of BioImage A/S, spun out of Novo Nordisk and now part of the imaging division of Thermo Fisher Scientific. She was responsible for the development of functional cell-based assays, and for their transfer to partners such as Amersham plc (now GE Healthcare).

2cureX share ownership and warrants
681 708 shares

Rosita Kaae

Director Business Development


Rosita Kaae (b. 1965) joined 2cureX in July 2022 as Product and Sales Manager.

Read more
Rosita Kaae
Director Business Development

Rosita Kaae (b. 1965) joined 2cureX in July 2022 as Product and Sales Manager.

Having spent more than 30 years in the pharmaceutical, In Vitro Diagnostics and Medical Device industries, Rosita has broad clinical, scientific, marketing and sales experience.

She started her career at pharmaceutical companies like Pharmacia, Alphapharm and Nycomed, moving then to the Medical Devices field. In the last years before joining 2cureX, she was Scientific Marketing Manager at Roche Diagnostics Denmark, and Business Development Manager at Mediq Denmark.

Rosita is MSc in Pharmacy by the University of Copenhagen and was until now in charge of 2cureX Business Development direct activities in Nordics (Denmark, Sweden, Norway and Iceland) where she established excellent relationships with KOLs in the oncology field.

2cureX share ownership and warrants
0 shares

Jürgen Kupper

Vice-President of Strategic Alliances


Jürgen Kupper (b. 1965) joined 2cureX in 2015.

Read more
Jürgen Kupper
Vice-President of Strategic Alliances

Jürgen Kupper (b. 1965) joined 2cureX in 2015.

He began his career at Evotec AG in 1999. Jürgen’s previous positions include COO of Evotec Technologies, Product Leader for Live Cell Imaging at PerkinElmer and Managing Director of the Diagnostic Center at the University Medical Center Hamburg-Eppendorf (UKE). Jürgen holds a PhD in Biophysics from Brandeis University, USA.

2cureX share ownership and warrants
43 400 shares

Tabea Sturmheit

Director Market Access Germany


Tabea Sturmheit (b. 1985) joined 2cureX in 2017.

Read more
Tabea Sturmheit
Director Market Access Germany

Tabea Sturmheit (b. 1985) joined 2cureX in 2017.

Tabea has a strong background in cancer biology & immunology, as well as stem cell biology. She has worked in several academic research labs across Europe (DE, IT, NL, CH). Prior to joining 2cureX, Tabea held a post-doc position at a Fraunhofer Research Institution in Lübeck (Germany), developing in vitro test systems for wound healing applications.

Tabea joined the 2cureX research department in 2017 and has since been dedicated to expanding the company’s product pipeline. She is a guest scientist in the Center for Oncology at the University Center Hamburg-Eppendorf (UKE) and, since January 2022, a member of the 2cureX management team.

Tabea holds a PhD in cellular and molecular biology from San Raffaele University, Milan (Italy).

2cureX share ownership and warrants
2 500 shares

Jacob Thastrup

Director of Product Development


Jacob Thastrup (b. 1979) joined 2cureX in 2009.

Read more
Jacob Thastrup
Director of Product Development

Jacob Thastrup (b. 1979) joined 2cureX in 2009.

Jacob joined 2cureX in 2009 as a Research Scientist after completing his PhD in Biochemistry from the University of Dundee, Scotland. Jacob has extensive knowledge of intra- and extra-cellular signaling and has worked in the field of cancer research since 2002. Jacob has more than a decade of experience developing in vitro diagnostic products for use in personalized medicine. As Director of Product Development Jacob is responsible for transitioning research prototypes into IVD-R certifiable products.

2cureX share ownership and warrants
10 919 shares